ARCA biopharma Inc

NEW
NAS:ABIO (USA)  
$ 25.5 -3.3 (-11.46%) 02:44 PM EST
At Loss
P/B:
0.95
Market Cap:
$ 369.93M
Enterprise V:
$ 393.23M
Volume:
-
Avg Vol (2M):
-
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
-
At Loss
Avg Vol (2M):
-
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for ARCA biopharma Inc ( ) from 1997 to May 16 2025. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. ARCA biopharma stock (ABIO) PE ratio as of May 16 2025 is 0. More Details

ARCA biopharma Inc (ABIO) PE Ratio (TTM) Chart

To

ARCA biopharma Inc (ABIO) PE Ratio (TTM) Historical Data

Total 1052
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 12
ARCA biopharma PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2025-05-16 At Loss 2024-06-28 At Loss
2024-08-30 At Loss 2024-06-27 At Loss
2024-08-29 At Loss 2024-06-26 At Loss
2024-08-28 At Loss 2024-06-25 At Loss
2024-08-27 At Loss 2024-06-24 At Loss
2024-08-26 At Loss 2024-06-21 At Loss
2024-08-23 At Loss 2024-06-20 At Loss
2024-08-22 At Loss 2024-06-18 At Loss
2024-08-21 At Loss 2024-06-17 At Loss
2024-08-20 At Loss 2024-06-14 At Loss
2024-08-19 At Loss 2024-06-13 At Loss
2024-08-16 At Loss 2024-06-12 At Loss
2024-08-15 At Loss 2024-06-11 At Loss
2024-08-14 At Loss 2024-06-10 At Loss
2024-08-13 At Loss 2024-06-07 At Loss
2024-08-12 At Loss 2024-06-06 At Loss
2024-08-09 At Loss 2024-06-05 At Loss
2024-08-08 At Loss 2024-06-04 At Loss
2024-08-07 At Loss 2024-06-03 At Loss
2024-08-06 At Loss 2024-05-31 At Loss
2024-08-05 At Loss 2024-05-30 At Loss
2024-08-02 At Loss 2024-05-29 At Loss
2024-08-01 At Loss 2024-05-28 At Loss
2024-07-31 At Loss 2024-05-24 At Loss
2024-07-30 At Loss 2024-05-23 At Loss
2024-07-29 At Loss 2024-05-22 At Loss
2024-07-26 At Loss 2024-05-21 At Loss
2024-07-25 At Loss 2024-05-20 At Loss
2024-07-24 At Loss 2024-05-17 At Loss
2024-07-23 At Loss 2024-05-16 At Loss
2024-07-22 At Loss 2024-05-15 At Loss
2024-07-19 At Loss 2024-05-14 At Loss
2024-07-18 At Loss 2024-05-13 At Loss
2024-07-17 At Loss 2024-05-10 At Loss
2024-07-16 At Loss 2024-05-09 At Loss
2024-07-15 At Loss 2024-05-08 At Loss
2024-07-12 At Loss 2024-05-07 At Loss
2024-07-11 At Loss 2024-05-06 At Loss
2024-07-10 At Loss 2024-05-03 At Loss
2024-07-09 At Loss 2024-05-02 At Loss
2024-07-08 At Loss 2024-05-01 At Loss
2024-07-05 At Loss 2024-04-30 At Loss
2024-07-03 At Loss 2024-04-29 At Loss
2024-07-02 At Loss 2024-04-26 At Loss
2024-07-01 At Loss 2024-04-25 At Loss

ARCA biopharma Inc (ABIO) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.